Key result
Ranolazine improves angina frequency and exercise tolerance, with potential HbA1c benefits in diabetes.
Why the study?
Despite optimal pharmacotherapy and revascularization, up to 26% of chronic stable angina patients still experience angina, and new antianginal strategies are being evaluated including ranolazine.
May support adjunctive ranolazine in diabetic patients with refractory angina; leaves open dedicated RCTs on glycemic effects.
Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardial ischemia have prompted evaluation of a number of new antianginal strategies. In this review we discuss the utility of ranolazine, a recently approved novel antianginal agent and its efficacy in the diabetic patient population. In addition to its antianginal action in diabetic patients with chronic angina, ranolazine may have favorable effects on glycated hemoglobin levels.
No takes yet. Share an insight, caveat, or question.
A 2008 study conducted a review in Chronic stable angina. Ranolazine was evaluated. Ranolazine is an effective antianginal medication for chronic stable angina that decreases angina frequency and increases exercise tolerance, while also potentially reducing HbA1c in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: